Paratek Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Paratek Pharmaceuticals

03/11/2022 22:27

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 38 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of 29 cents per share.
    * Revenue rose 23.6% to $30.21 million from a year ago;
analysts
expected $34.19 million. 
    * Paratek Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Paratek Pharmaceuticals Inc shares had risen by 30.4% this
quarter and lost 25.4% so far this year.
    * The company reported a quarterly loss of $20.88 million.
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $16.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 10:27 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.29          -0.38          Missed
 Jun. 30 2022      -0.34          -0.33          Beat
 Mar. 31 2022      -0.35          -0.35          Met
 Dec. 31 2021      -0.41          -0.66          Missed